Tolka AI Therapeutics
Developer of personalized bacteriophage therapies targeting Mycobacterium abscessus and other antibiotic-resistant infections. Combines patient-specific phage discovery, a cGMP-oriented manufacturing pipeline, AI-driven genome and host-range analysis, and clinical/regulatory pathways (including eIND and expanded access) to deliver investigational, small-batch phage products and related research resources (biobank).
Industries
Nr. of Employees
small (1-50)
Tolka AI Therapeutics
Products
Investigational personalized phage formulations (GMP-grade)
Small-batch, patient-tailored phage formulations produced to GMP standards and purified to reduce endotoxin/exotoxin content; designed for refrigerated stability.
Investigational personalized phage formulations (GMP-grade)
Small-batch, patient-tailored phage formulations produced to GMP standards and purified to reduce endotoxin/exotoxin content; designed for refrigerated stability.
Services
Evaluation and provision of investigational personalized phage therapies to eligible patients via physician-request under expanded access/eIND conditions.
Collection, de-identification, and secure storage of patient respiratory isolates to support phage discovery and future personalized therapies and trials.
Evaluation and provision of investigational personalized phage therapies to eligible patients via physician-request under expanded access/eIND conditions.
Collection, de-identification, and secure storage of patient respiratory isolates to support phage discovery and future personalized therapies and trials.
Expertise Areas
- Personalized bacteriophage discovery
- GMP phage manufacturing and formulation
- Phage bioinformatics and machine learning
- Clinical trial planning and eIND submissions
Key Technologies
- Genome analysis pipelines
- Protein structure prediction
- Machine learning for host-range prediction
- High-throughput plaque assays
News & Updates
Discussion of technologies for generating enhanced phages and optimizing phage cocktails to address antibiotic resistance and microbiome dysbiosis.
Article covering company activity in developing phage therapies to address antibiotic-resistant infections.
Podcast episode featuring discussion of personalized phage therapy and company activities.
BRANY IRB Study #25-08-468-1945 for a patient-focused Mycobacterium abscessus biobank.
Discussion of technologies for generating enhanced phages and optimizing phage cocktails to address antibiotic resistance and microbiome dysbiosis.
Article covering company activity in developing phage therapies to address antibiotic-resistant infections.
Podcast episode featuring discussion of personalized phage therapy and company activities.
BRANY IRB Study #25-08-468-1945 for a patient-focused Mycobacterium abscessus biobank.